XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Warrants and Derivative Liabilities | 9 Months Ended
--- | ---
Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Warrants and Derivative Liabilities | Warrants and Derivative Liabilities The Company accounts for its warrants and contingent consideration as liabilities due to certain adjustment provisions within the instruments, which require that they be recorded at fair value. The warrants are subject to revaluation at each balance sheet date and any change in fair value is recorded as a change in fair value of warrants until the earlier of its expiration or its exercise at which time the warrant liability will be reclassified to equity. The Company calculated the fair value of the warrants utilizing an integrated lattice model. See Note 6, "Fair Value Measurements", for further discussion. Hercules Warrants The Company issued Hercules warrants to purchase 13,927 shares of common stock (the “First Warrant”) and 25,641 shares of common stock (the “Second Warrant”) in conjunction with prior term loans that have been repaid in full. On December 19, 2014, the Company entered into a second amendment to the Loan and Security Agreement with Hercules (the "Hercules Second Amendment"). In conjunction with the Hercules Second Amendment, the Company issued Hercules a warrant to purchase 58,823 shares of the Company’s common stock (the "Hercules Warrant") which replaced the First Warrant and the Second Warrant. The Hercules Warrant is exercisable at any time after its issuance at an exercise price of $7.85 per share, subject to certain price-based and other anti-dilution adjustments, including the equity offering in May 2017, the acquisition of ITC with common stock in September 2017 and sales of common stock under the ATM entered into in January 2017, and expires on June 30, 2020. This warrant had a fair value of $0.3 million as of December 31, 2018 and $0.1 million as of March 31, 2018. November 2014 Warrant On November 13, 2014, the Company completed an offering of 909,090 units of the Company’s common stock with Hudson Bay Capital. Each unit consisted of one share of the Company’s common stock and 0.9 of a warrant to purchase one share of common stock, or a warrant to purchase in the aggregate 818,181 shares (the “November 2014 Warrant”). The November 2014 Warrant is exercisable at any time, at an exercise price equal to $7.81 per share, subject to certain price-based and other anti-dilution adjustments including those noted above, and expires on November 13, 2019. Following is a summary of the key assumptions used to calculate the fair value of the November 2014 Warrant:
Fiscal Year 18 | December 31, 2018 |  | September 30, 2018 |  | June 30, 2018
Risk-free interest rate | 2.61% |  | 2.62% |  | 2.40%
Expected annual dividend yield | — |  | — |  | —
Expected volatility | 70.29% |  | 63.66% |  | 67.40%
Term (years) | 0.87 |  | 1.12 |  | 1.37
Fair value | $3.6 million |  | $1.3 million |  | $1.6 million
Fiscal Year 17 | March 31, 2018 |  | December 31, 2017 |  | September 30, 2017 |  | June 30, 2017 |  | March 31, 2017
Risk-free interest rate | 2.20% |  | 1.87% |  | 1.49% |  | 1.44% |  | 1.41%
Expected annual dividend yield | — |  | — |  | — |  | — |  | —
Expected volatility | 65.86% |  | 65.86% |  | 65.64% |  | 67.21% |  | 66.53%
Term (years) | 1.62 |  | 1.87 |  | 2.12 |  | 2.37 |  | 2.62
Fair value | $1.1 million |  | $0.4 million |  | $0.8 million |  | $0.9 million |  | $1.8 million
The Company recorded net losses of $2.3 million and $2.5 million resulting from the increase in the fair value of the November 2014 Warrant during the three and nine months ended December 31, 2018, respectively. The Company recorded net gains of $0.4 million and $1.4 million, resulting from the decrease in the fair value of the November 2014 Warrant during the three and nine months ended December 31, 2017, respectively.

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -URI http://asc.fasb.org/topic&trid=2229140 + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration